Status:
COMPLETED
Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis
Lead Sponsor:
AstraZeneca
Conditions:
Reflux Esophagitis
Eligibility:
All Genders
Brief Summary
This open label, non-interventional study is to compare the efficacy of Omepral® tablet and any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various type of acid reflu...
Eligibility Criteria
Inclusion
- Patients newly diagnosed as erosive esophagitis or history of erosive esophagitis confirmed by endoscopy.
- Patients who answered questionnaires of quality of life (QOLRAD-J), symptom severity and frequency and treatment satisfaction.
- During the past 1 week , patients who have either two days or more with heartburn or acid taste in the mouth of any severity
Exclusion
- Patients receiving treatment with proton pump inhibitors, which make stomach acid decreased during the last 4 weeks prior to enrolment.
- Patients who cannot answer questionnaires of quality of life (QOLRAD-J), symptom severity and frequency and treatment satisfaction.
- Patients included previously in this study.
Key Trial Info
Start Date :
June 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
10703 Patients enrolled
Trial Details
Trial ID
NCT00859287
Start Date
June 1 2007
End Date
July 1 2008
Last Update
July 15 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.